<SEC-DOCUMENT>0001193125-17-350676.txt : 20171122
<SEC-HEADER>0001193125-17-350676.hdr.sgml : 20171122
<ACCEPTANCE-DATETIME>20171122160606
ACCESSION NUMBER:		0001193125-17-350676
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171122
FILED AS OF DATE:		20171122
DATE AS OF CHANGE:		20171122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DBV Technologies S.A.
		CENTRAL INDEX KEY:			0001613780
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36697
		FILM NUMBER:		171219941

	BUSINESS ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
		BUSINESS PHONE:		33(0)155427878

	MAIL ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d486105d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES SECURITIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">6-K</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Month of November 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-36697</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>DBV TECHNOLOGIES S.A. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">177-181</FONT> avenue Pierre Brossolette </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>92120 Montrouge France </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F:</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9746;&nbsp;Form <FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&#9744; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated November&nbsp;20, 2017.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DBV TECHNOLOGIES S.A.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;22, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Schilansky</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Schilansky</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Operating Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d486105dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g486105g86p18.gif" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Press Release </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Montrouge, France, November&nbsp;20, 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><B>DBV Technologies Announces Positive Topline Safety Results from REALISE Phase III Trial of Viaskin Peanut for the Treatment of Peanut-Allergic Patients
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Blinded period evaluated the safety of Viaskin Peanut versus placebo in children four to 11 years of age, Including patients with a history of
severe anaphylaxis </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A favorable safety and tolerability profile was observed, which was comparable to data from other trials with Viaskin
Peanut</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>These results, which are part of a global Phase III program, will support planned regulatory discussions for Viaskin Peanut </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies (Euronext: DBV &#150; ISIN: FR0010417345&#151;Nasdaq Stock Market: DBVT) today announced positive topline results from the Phase III REALISE
(REAL Life Use and Safety of EPIT) trial. The REALISE double-blinded period compared the safety of treatment with Viaskin Peanut 250 &micro;g versus placebo for six months. Patients who completed the blinded portion of the study will continue to
receive active treatment for up to 36 months during an open-label extension, further studying the long-term safety and use of Viaskin Peanut in routine clinical practice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The REALISE trial met its primary objective, demonstrating that Viaskin Peanut was well-tolerated with no new or unexpected adverse events. Based on
preliminary analysis, a similar safety profile was observed in all patients included in the trial, regardless of history of severe anaphylaxis. The safety data reported today complete the Food and Drug Administration (FDA) safety database
requirement for the Viaskin Peanut program in children four to 11 years of age. Results from this study, in addition to data from the PEPITES Phase III efficacy and safety trial, will form the basis for planned regulatory discussions in the United
States, Europe and other countries for use of Viaskin Peanut in this patient population. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr.</B><B></B><B>&nbsp;Jacqueline Pongracic</B>, Head,
Allergy and Immunology, Ann&nbsp;&amp; Robert H. Lurie Children&#146;s Hospital of Chicago, Professor of Pediatrics and Medicine, Northwestern University Feinberg School of Medicine, and Principal Investigator of REALISE, said: &#147;<I>As more
patients are treated with Viaskin Peanut in clinical trials, our understanding of this novel immunotherapy has deepened. In REALISE, we have observed that using the skin to activate the immune system of these patients resulted in a favorable safety
and tolerability profile, likely contributing to the high compliance rate maintained throughout the blinded portion of the trial. The medical community has been eagerly anticipating a </I><I>treatment that could be effective in real-life, and I am
excited to have been part of this groundbreaking clinical program, which may bring us one step closer to meeting patients&#146; needs.</I>&#148; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Results from this trial were comparable with outcomes from previous studies of Viaskin Peanut 250 &micro;g. The
most commonly reported adverse events were local application site reactions, that were mostly mild and moderate in nature. No imbalance in serious adverse events (SAEs) was observed in the trial, with 3 cases in 3 subjects in the active arm (1.0%),
and 2 cases in 2 subjects in the placebo arm (2.0%); 1 case in 1 subject in the active arm was qualified by the investigator as moderate anaphylaxis probably related to treatment. The patient responded to standard outpatient therapy. In the <FONT
STYLE="white-space:nowrap">six-month</FONT> blinded period, the discontinuation rate was 2.5%, with a 1.0% dropout related to adverse events. Mean patient compliance was above 95%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&#147;For the millions of patients and their caregivers who cope with the tremendous burden of this disease daily, offering not only an effective medicine,
but one that is safe is so essential,&#148; </I>said <B>Dr.</B><B></B><B>&nbsp;Jim Baker</B>, Chief Executive Officer and Chief Medical Officer, Food Allergy Research&nbsp;&amp; Education (FARE). <I>&#147;The data from the <FONT
STYLE="white-space:nowrap">six-month</FONT> period of this trial underscores the favorable safety profile of Viaskin Peanut, which has also been observed in previous clinical studies. We look forward to seeing the long-term results from the rest of
this trial and understanding the benefit of this potential treatment for patients.&#148; </I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, over 700 patients have been studied in the
Company&#146;s ongoing Phase III program in children ages four to 11, which includes both the PEPITES and REALISE trials. A Phase III trial is also ongoing in children one to three years of age. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&#147;We remain steadfast in our commitment to bringing a treatment to peanut-allergic patients as soon as possible,&#148; </I>said
<B>Dr.</B><B></B><B>&nbsp;Pierre-Henri Benhamou</B>, Chairman&nbsp;&amp; Chief Executive Officer of DBV Technologies. <I>&#147;This trial, which was the first Phase III trial to study peanut-allergic patients in the absence of food challenges, is an
important consideration in understanding the use of Viaskin Peanut in a real-life setting. We are hopeful that data generated from REALISE will continue to strengthen the profile of Viaskin Peanut in routine clinical use.&#148;</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Detailed results from this study are expected to be submitted for presentation at a future medical meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About REALISE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REALISE is a multicenter, randomized,
double-blinded, placebo-controlled Phase III study designed to generate safety data after six months of blinded treatment in 393 patients four to 11 years of age and assess the use of Viaskin Peanut 250 &micro;g in routine medical practice. At the <FONT
STYLE="white-space:nowrap">six-month</FONT> time point, 383 patients in both the placebo and active arms continued in the open-label portion of the study, which will monitor patients for a total of 36 months of active treatment. Exploratory criteria
also include scores from patients&#146; Food Allergy Quality of Life Questionnaire (FAQLQ) and the Food Allergy Independent Measure (FAIM), as well as the evolution of peanut-specific serological markers over time. The study is conducted in 32
centers in North America. No oral food challenges are required in REALISE. Patients in the study were selected based on a well-documented medical history of IgE-mediated reactions to peanut, including children with a history of severe anaphylaxis,
as well as analyses of baseline peanut-specific immunological markers. During the first six months of trial, patients were randomized 3:1 active versus placebo. Key assessments of safety parameters include treatment-emergent adverse events observed
in both the placebo and active treatment groups during the initial six months, which continue to be monitored during the open-label portion of the study. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About PEPITES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Peanut EPIT Efficacy and Safety Study (PEPITES) was a global, pivotal, double-blinded, placebo-controlled Phase III trial designed to evaluate the safety
and efficacy of Viaskin Peanut 250 &micro;g in children ages four to 11 years. PEPITES was conducted in 31 centers across North America (Canada and the United States), Germany, Ireland and Australia. Topline results from PEPITES were announced in
October 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During PEPITES, patients&#146; response has been assessed using a double-blind, placebo controlled food challenge (DBPCFC). Patients were
randomized 2:1 to receive either Viaskin Peanut 250 &micro;g or placebo for 12 months. The primary endpoint was based on a responder analysis after 12 months of treatment with Viaskin Peanut 250 &micro;g. For patients with a baseline peanut protein
eliciting dose (ED) equal to or less than 10 mg, a responder was defined as a patient with a peanut protein ED equal to or greater than 300 mg of peanut protein after 12 months of treatment. For patients with a baseline ED greater than 10 mg, a
responder was defined as a patient with a peanut protein ED equal to or greater than 1,000 mg of peanut protein after 12 months of treatment. As a secondary efficacy endpoint, Cumulative Reactive Dose (CRD), has also been used in PEPITES to
establish the total quantity of peanut protein that triggers patient reactions at month 12 of active treatment versus placebo. Serological markers were also measured at baseline, 3, 6, and 12 months in order to characterize the immunological changes
in patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Technologies</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies is
developing Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, DBV&#146;s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and
<FONT STYLE="white-space:nowrap">non-invasive</FONT> product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV&#146;s food allergies programs include
ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares
are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing
<FONT STYLE="white-space:nowrap">one-half</FONT> of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: <U><FONT STYLE="white-space:nowrap">www.dbv-technologies.com</FONT></U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release may
contain forward-looking statements and estimates, including statements regarding the potential of Viaskin Peanut and the Company&#146;s regulatory strategy related to Viaskin Peanut. These forward-looking statements and estimates are not promises or
guarantees and involve substantial risks and uncertainties. At this stage, the products of the Company have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or
projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals and the risk that historical clinical results in one patient population may not be predictive of
future clinical trial results in different patient populations. A further list and description of these risks, uncertainties and other risks can be found in the Company&#146;s regulatory filings with the French Autorit&eacute; des March&eacute;s
Financiers, the Company&#146;s Securities and Exchange Commission filings and reports, including in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2016 and future filings
and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV
Technologies undertakes no obligation to update or revise the information contained in this Press Release. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Investor Relations Contact </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sara Blum Sherman </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director, Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1&nbsp;212-271-0740</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">sara.sherman@dbv-technologies.com</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Media Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Roberta Di Giorgio </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Head, Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">+1&nbsp;917-612-2861</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">roberta.digiorgio@dbv-technologies.com</FONT> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g486105g86p18.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486105g86p18.gif
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MWN?O]X2<SFN$A'.,E(2ESD)[O6.<WF.4UHREQFN$M4I[G)2EI7N$C$)[I0
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M(0]<VDKH1K (HH@D_D S3$ZJ)S>=P*Q)Q#/,T>IVD:X\YWV!^UJ79'=!C9Q
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MJ*2&0OIM8D)0^N*>17"APE@)M21"+"QKD,#I)%$TCV,B5EFFG3$"\AY#?1F
M]@])O!$IV@62KI@D%4"[R11CL#L9J%WHW#?+(JI>TI6[4)0^O_094F9=292F
MD"44\I&>J!.600\-/MK4B=:?:RBG^^LH8%K(7C[3E!JH#B(\=\OF7S)Q$')H
M?9I_39$F<G14H^A3[&EYETZ/,/5B>"!J"AB%X'4\R\01D;CS35*2 MTTOD5.
M;9+5ROM'2Y5JTLG)Q--)Y6*GG.Q+(["QDIM*_BFOW(FJ?^QR.X#"0BG$;^7:
MDDS- "L2$SKE$M1X3):G5S61YRBD\2.%&? +HL>"(#II-; ED_4117)\S"=&
M)]%5_.9*?!0:(85%1Y$ 8[42_D%(LT9=DG%J,9(U;4%\4A(X;2$UI:4<!Q$:
MQ90[['<S?V(;1X%)F (B/=)ZLG)Z,[A9^9(T6I)PQF%6-P@@?86#+8A/T>06
M;\(R4+%L2+%0G9%Y_B(RGZ)8C+5#1\(L"P,@ZO)I'(-JOV0K"Z=D>@0J1^8
M7J( 5U-?@5-SG.%Q2JA->V0K##%D9*$LT189-9!&G:03X7(0.E%^BP%I2\$K
M:I$N+6$1V=0;)P H_H4Q::L':5;11YPQ$]!Q9ZE%.FUA'?[B*AZE$3?A9,)$
M<P%V08C3?5'Q,N3!&O\4%=XD&V^!++@G&3Z4-",15\"$.Z]U8U,E(JK#*O?7
M -1"276!=E\U9 \$5X5A/@#B=3P"4\Z7$B !*+*H%%55.$>&>#*AA!0A-WQ$
M-_/!,D%"$MVD)$ME&#-#$*\"/[WQ61]R(8*2$TP(9+TU/FS7B6L"*[9H)S'E
M+A^'> N')NHA8WJQ6HIT,*A8%.YA%AW!=R&%A.:3=@2'=NIR,]!$*<54,DY'
M(6)H$V3Q(U^B2RP!,$S(/4C"&=;R'*11-IKQ2JX$&\*H7 VA1]!C$IW%_E]E
MJ"(4HDMY\6M+45-P075!\"%M(89W52RD@DBE52-J$D E81RA0A#B%HA+Y2\O
M$7[Y56*R11R8=P0TX729EQA/<7H(9')(UB#L=Q$MT1(=42^;"'-'HFBRDA;E
M-G'C=A,0<P* ^'TU<2HLIRD3TH%-TG*7L1 MX5^"PS)O50/'AA..HBJ)HBD:
M27X4 1>*!B%,P97D@7"5V1N+TP5=P#(V< -G\ ,#(0%W<@9K4 4O\ *&4 <S
MT >34 17P *'8 ,=<V5#T3/WMX3TL64N>8J8V5!]]!.F   _06E6!"N(<A88
MLU15<F1[<R<8HV1HTA9M%XBX]X:">#4>Y#JE_J@F/<4B-6665=:+ B2-9$0B
M&".+TSD^I15R%60QPM0Q - 7\=DK;/@@&F<9*%&)@/-*## ! T$!,B !\ND7
M*2 #$V 0_EE)$A 5%20!?00F9]E'%Z-/T@%0'3$!_2$1_EE!M"B+MP$M)9,R
M1>&@^N2- ^&?"9I[)PH #FI=)+H?*7"@DW4 *9 "_:F1D?)=H,9LMB@7!WH
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M33 1YCE1$#5JE>H&!E_ (+\) FYRTSV:: !^8XW,I[:,%MHIH%9_$*;I$'+
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MD  #> #(   _G0 )N $J$ "$G  4H("1H !,\P$@$0 94$.G4%8?Z(D#_DB
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M"#[HA800O7'E@X]E@0L(B^M0. GH@D&%C24QGY0@5IR @*==@'/U 9DP(@G
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MZ!#:[(A%,A/1R(R8M-/VX8R!J($484PO(<;A,,#,I)ES AF:&R=P2:"<_DG
MJAC:T D  J(KF> (:[G8"[@":&&!Z2F"YF6!"F#@);&+"E.S-): ^L")D5@2
M&Q""/3B$&_"!\_EA'H:6*V@!'_#C'-D5&>B"VEH 0XB$/(@$JU@V&^B%  @
M.&")3$"")("";4BM%KAH&T#:/D2#YM4!JMT#'>@!&S@$C+:! #@!/GYH&[8#
M6^P)S,,"T!.19?L!'S@W ,"/0]@#G+ #7P+JE%$ %6")%FB!L;@"%G"F.'@!
MJ4"#*OA4_%B+*Z #-%B#73G7"L.!-7 "** ]&Z  "<!6 .C#AZJ.76E>AV:
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M !>8=N%'<Q10A./-G@MHK2*  04X QNUT6.& NGQ:1LH!>K7'B4@?CP "!D
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M#(9.'QJC_- &0Q<$,7"$@1 .(.7  NP%-E4,#0UP'WDUN%?> @+-9QX #CB
MPU86.#!&$D+ 8($9@PC@ '48R<"  N8QT!Z% !3H0'DGX(<>1@M4-T!5_@ D
MR( ,).X'@(P-'#  +NI1>%\0PPSEP E!V)@@C":Z^&".*1K@'@/JQ= C R0&
M41Z-,E:U()CEN<>D>5'Z&!&-EI4I97DINBB, ;PM<,("1E[9D $$5G6##4SE
M4,P"/A!W4@LM &H!-$-!=0$>-NAP!5,7\$F?>6%<L ,..^P "$)(J'>2!4]P
MRL(5%P"B@ -67,#6%3"Y8T45.D!E@0H3/.3B @I$=,$5-@AA! QWH($""DC
M5$0QD5R!!D(-8-'"6Q=,98,3%BP!A0YQ7=!$ISKL8($+0^E@5A$O7#%)$3E
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M.(0-U(.4B$P $K$2@AF"$A&B_(1[$W"+I'X2 5BXZP]V>=6_"@4%G0B #WE
M"+X8H$7WG ]8= Q#HA)EA##DH K8 1:!=&#(/ !L>N(*#'RL.*(%Q,X'$%G
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MQ!XV^18AV!4.!K4 =M@! _=HKPDGX9P-E&*3B<* )JR*B!93%!0;Q,X!#X
MZEI !D3Y:@$-0)D/?' %1+RX%RQEA&+.XYX2D7*U-,6I[QHR'^Q<1T5&_I*
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MCB2/7270E9"<$9K'I2206BU D=Q@:MD( 950@L3 87$?5PV6[NB)C336$ Z
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MB-$"M(&[S(=%7)4 _B#$3YR  J!"&\3?L\HAI6IK!Z) O=A*'=G(KT7$)J"
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MA%:H'0/8"J3D1$*H1^S\0!3 P2P&!>/DAA)(#SNAA,M$0>2V:1JT02W$@/0
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MIC1!=8R!YD&!5!+(#CC!]+5 $>  A!\ #"6*"[A E:Y.YZ"!$[Q9?865$_B
M."@I&L@$8M(NO&'!*1115; *&E3!.$2!V!@ .4!PH0Q!':Q!$:W.G0!*Y&(,
M"S0!""=9IZ!!KTP/B?A*$U & -2*=YOY$&S)?$",_WE8_@A ENM'=21!/BT
M=D"!%3#"!<@&@4Q #'0*H#AM#^39!'@"%J !&M2!. !,9B*R2LG/$-B!J:IV
M&ARY &QD%4!+$=Q!N]Z' MQ A1"(&%4!AA1!&N@ 'A2!^\( MYCKWZR-_GD
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M/@02$.!4:6Z@RC+7='#B(BPX78"A  :@<X&(<EC#.'336L"&$U28H"# L&!
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M\$T2'Q2QP((8=?,\/2,%'*8;Y_!.P"^9$ .#SO50F%,>I<+UIG/'OI/S $U
M2NCT. B)4*PO# <JODPX,"M+O/ ^ M;;/I-3'=4*4[5]/B2T/-)E"N7: N1"
M+S4^1B*M4K$XJ@Q!C\4%75!/)L  =M%C@B<ZE^QCF;-<Q5("EN_ZT(:1'*";
MI"*9-$A/#D,"H+1M_D;Z&. 0>B 2=F F=" -_LQ$Y$A'YHII]21.14A!=0P
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M(V8/Q4'%TC;MR OY2;$ JR)'R.V2I2O,ES<0Q6=$*36X:S@<U9EP R#[R,#
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M,B=\'VF","&KR, A-*E!5Q@"LDE%9#!-*MR%.,BQ&Y40313A5$/<1)J67 R
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MR44O@&& 6,EJT;EY:4P#,6Z1'K0JCR@6A7:57T<BTQ(++4NE:PT)_YA7E-X
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M&EPS30YA>UA(%B(8!!#!/ZZ8,:-D7/LSC!XB;Z@"49\W,S+ /P4@  %@'3=
M!,1C ;*4*.\S+:]T#,7P>/2#=CC#;;Y!<;0S0F4D62HG$V,14D8R,0>1(.'E
M@8\T;J/F:PU#0G8A&75A$33Q4G#S:%)7&@O1_A5-1!I\]3A;DT.!D4;G%A4U
M 1L#5!1XI#/_DQ$N2$ Y 4<7(A8.E7 K@R@> 2BU"":Y\19;Y'_AEFTAMI Y
MA2$B&1'Z01NK4Q-N:%)&(1</A"9@Z$Y"X16G<A JAB%74C6;-Q+(8AI><0*T
M<2SP,0 ;L9*3!4@5L2EYI6Q-4E!@4A(6.7>3,A00^8 -]&$BD16N8RJ#"$1*
M@GB@)C$GH)(/Y)&WYY+8.)$4\F(/4F%,PV."4DT$)F,ULD)QLX@/8@.5*8YP
M< !08 RCA8XNP9G$(0P+\ ,^X ,VX"R5A91@T1(<I4>3Y7TWL9I$4FM8XY.*
M(4.3TB<'B9!P82,^_OB88)088 )<&?$_P%(U6"$VF(,@:7*-?T(G0!-/%Y8E
M V!=#W5TAD=NF386+EE"@ 0M=W-T%H$^8LEX3S,I#K412Q-?6/$:<'(S#X<S
M<%$2V547]!,2L%$J$))7_Q$L2N@UFR* 3"%AKEEKEF)3R*@9O(8?F.0G64%.
MG >;VTE*/D(BV:4 9S$2B,% B$*<E[@R"849Q]>:R[=!9!,1X$9O9.(A"+)=
MZGF=0/)Q,=EOJG@35+$F+3%5;W*2*H*" C$:$;.)^'$1@[E>.SD6:;0\O\E$
M!<84<+2:4=9O@><0E5F9<(  C0  -@ %L<29G*D%,! '+4"EE>D#*S,B_LSE
M6'53%"7",;[1%I.!+%QR&TKAA;+A@<L9-?-D5\HH-K?685!:2D(BDY6!(*NA
M(ERB%-2F3B>V.)!22IZC3MMYG:9&&H]1$>S),3ES5@IYDJ-&E'=Y5D?Q$ZGQ
M=C0X&&Y(1SS">;46$W3T*/-U;G4Q7FFQ:CA*??\#$<4B9**B )(#-DFX(K!2
M-E:A7F_($&J#(05F)JMI% V"8FZR%/790X/A34<!%U"!:@C# "E5<6IBI\F*
M,.X6K+&!:(*S@B!Q C!1@EL4$WV*C0(!.I?*ILG$FJG1D=@J,B'$0:Q*0AG%
MIC"B:GSBK)AS;?"I3@*79 JP;]'J,6@**"[$_A_B"E*,(V1=-*E1@8MRHC[!
M^3@3D *,@074A@(30#PE6[)10&)Z(0 W$ !3J14?*"J7(A%'^45%)!&."B3#
M>$5H48>!H2+Z9AI\M*9!9BT,A"H0$AD"""8]%G@WT@ KL2(TJR(J) -H R'?
M]1-+02D($0 W4)D)<!XNARD ( &6-0$M,0$%U&1$>T(%85SW8425* ,2H! 3
M<+9J2QL28%=4P0!P>W6E9+=4U!T30+<J-0!Z>S-INU(&( '= 0!G.P'H5XDW
MX;=5X;<J-5-E]A I<!^^ 7V'(P&,>Y:AJTB)6T!UH;<?P5&I6T242Q!E&[1$
M^[@ED;8&0+B.*[O*_L:YJ;L0<_L0<#L!%$"VRD*VC>L=$O">.M2W"R$9):&W
M^V.[!B!6:?NXC'L3W9$"762VOB$FV7L >IN]FJ-[J7NYC_NZ2U6X'U&[LP$1
M$A #H4M6>INZ#,"[YDL0*3"XC^J-B!L1D7L?:EL0=*M;1?-X?C$ ^C%=D1IB
M=@55/D2V$^$#:J 9"#&RD= $Q; #D5 ,]9*N2A*:ICF?I*)5=XI8:+-![?-8
M9"<T,-)0: C (=5Y;HF&G,-#DKA7CG1W9#) !^4E)HR7UF,0;UH#8I,C:^(4
M,+(T)2R,@8HRN&4D'/54!;9!\$$_8*L -W $$E&U\=2X[)L0$M  J>MU_AY+
MME@!M_\B/]UA'Q, M0P0O@"0 K;;MYS[OUOUO4C77O;1OM=H -F+N$AF&&_L
MNQO3N2M!MXS;N/ ; VE['Q,AO)CG$N37 ,*+$()L'VT<OJ&KJT_B*(3[O0TH
MN.=V,WL,$6<\ ?!WOY=\QV@BQE1CO8GTNJ1,OU-)MCT4QA?B%XS[R3%AN\$%
MMV(A <.(O(>[5BR1O>WKQ0A4N_2;MM\+2'&L$88,)/#+N)S1OA)  6\,$4%
MO>8KO/=Q,PEBMT_2MU5!?G$LQL8Z5CP$MS+@O9T!R,@+)+Y[)8<, )9# ;R7
M583QHR@A$EOG8/2C%PYP PYP!K&2I0( C0^A_K<%@'(G:<MI=C1_:#(!95..
M!+6*P79H57:%]&\EX8;3Y%]X(FN\B$#Q9!)9Q(LH34P9P2<'*S0@!#CM-8++
M,XND$E!D@9@D*IS/A%NDPB'N/+-;;! *+96V^V"O3!.(I']\4Q"49!/ZEZL"
MH;?71+0FQZT;E%(T,G_56R1FC!J\R\N :]599Q/_"X1,Y( 2\(R<<1_G1UT%
M<<9C,M6K_*0$87+V6P,I9=5IR]9277,->',N\=8UP=1VJ\=T3;UG3"2@ESZX
M(=8@F8A,#%,N>,_&U48.%CG#^+]L_-CF.]9N"]H!9+MPBY^AT<4,'%\9721G
M'-E$,B36I5$CM+XG_AVY<T,0W8QB*<(A-[HS'HT9RK,?RM9:#R( "9 9\*$9
M)(80YU%=!($" %  'R&LC%>44,1=_[9%M4)6M^<@DF*G$%(Q'-);?=4A1QL_
MDO:H7.$G2+4:R5T:9WF6<E*%RWI;-4IN2U&NDMHC<$L,=/M%.(8>-S$ EQN;
M<K9^#7,:N.&W!GX?P)O; 300_TLD':(ZHAWA$\"MYIN%#H:02TRY8I7:<,O-
M5]?A]LO @-O,"(G8'\XE7!(3A)O;]%2^5GVH'=+82.$5/7.V'G[A+0.Y]NO4
M2&&W)]XP!KXR/<[$$@[%7O$DC_O@'TZVKVNW52YG2\?:EXOD1@'AU1DH_F@[
M8 XVX4J^,D[-K$N<7U_1JW1)&"B:D$'Z%1)! 21V!5<P WVP5W)1!$7 QMY!
M$=XA$.(8C@F 'CW;DDVR)HJ$77RR?<L3WQ)%2$9GTBK5%I9!89 *>]B9%N[C
M(/14 _NJ&5*!LSSA0"+A7W=Q)Z5>C$*UG4].$X0T+'<2AL2Y56X<0B"2%R=P
M XG\(L5" 0!.OWXL ]YQO!1@MQ1P>8WK)J7\P Q@[' T$L..S7KK'<Y.$,;^
MN(W[ZWYMO \AO!1@[,KN)K^^*.W3'0 ^['Z=VQ*0 K_>Z'*>$/C;R,';MVL2
MS,BKQ6B!S09!M\8+[K-!R4LQ["Z!NQ0 []E._M@##^@4L+C]&TF1E,@30$^4
M3.QSZ^S$CA#&[NQ'8.7_W@"<6[RAB]@2<>^66Q6#2^\7[[?0C"" _L</W[>1
M^LA",^WJ-,L 8/!+G+HR8.RH&_/2)^? #L=DFR%V>SGY_+H>1 $'<>X'\.L_
M<KLB/^V/ZSF(C;O3[MG43D4VB;9IF_$@4=5N<>YZ:_">3;:GS//[;DW^Q94/
M82)1M28G (]<HP"<>R0LP(!<(0 -$ /%$;SH<Q_B&  *(.@"4(S,TQ\V\S,L
M91L_:"1A(A(?5EO<JQN:]% E!HV.,7=!X#'!F-161AK'ZB4V*(Q8E:Q'T79,
M=2DFP:;0:IVD6#.3_NE!LV,7!^%H3^M5&Z( PS $"P"W^"NK8[[M0IT6W7&L
MV$R_VNZQ-3^WP_[K#5+:?,O,N5T7A'L0U6ZC[(Y3'RN\2#U-352X;FP0PON\
M1['TW7\4^_[M<CX1H5O^%+ 12T_U"*'MI7OS*?#QD70 G,N('-_^# \0,A@P
M '!@( ,*% X> -#0@ $*$@P,/" AHL(4$RQ*P'5 !@ )$A!*D"$CHP20#0'(
M,  @AH&0,1BD* E X82/'RD 2 %@PLZ$+2<,!&E1($&0 Q,2%*HQI\V!*68R
M@#D0YX04%*1J;#C4@ R-$WW:A B@)8 &/WE2;4@A1E &,4(V$/E5Y4 )_C@?
M2AQ*L*?"HRT?PBS:H"%+!AHG='TX 6M*LW9;,A H=:>!Q3ME-)"1%V51"H8!
M)!9I,2'4H20G8&[(@.'H!0 <F!T]&\  JBUC,'SX<O3O&S:*6( !@Z$  5VZ
M$+][, :"E@6D'Q \T4%L P, G"#H@.EOV10;QF;;FH&"\^@/VJWAP/9*E?&1
MSB:Z@*!K@KCOPQ\P$2E+VN)R2*78 +#O@-?,0HHI!OIS+8;(RB-H@;,62- @
M^5YSX #MX(NO)05T8\J MR1  0 4+"IJ 0=TL &-'6Q88,83;)#QNAL<4""X
M!6S0L48%>NS1AA-FE-%'%FU,$DD;KW/ !@5D_F31 3,6.&$(&VV\X88%%'!O
MQBZE[/%))%GL<LP9N3PA2&%Z5"#((,6,$\TCLSQRQB?'#.[)Z^",TH9!NN22
M2R$'^=)).Z^C$4SWJKS2SB&*-.-+&J4D4T@; Q5241D'.>'0!8*[(4HP@SRS
MSAKS!%/,&4U%TD\D'5@3RBG=V[/.35?ET\P>AYA22QUY=>"&(H/<E5(?^;S.
M1R*5Q!%*'EE4H$8NQ21452'-9'(!0YDEU4Q'L<S26#N4Y#70)K/$\TSW9,QQ
MQQNA#/)6&_\<DUD''I+-I<C.,L]? XDR3P&5)I!Q!@LPP*"  YY$J+B#HNHI
MB((*   !%0IJ;5_P_HY"*C*!1AO1/_(4C/ADV5JRC3R[,'1-7^]:^ZJ[]T)N
M*(;W_E-IPP5DJ&&RV5[2MR';#+#M/@8*3!F\T0YX4^G8 "QPMJ%%'LB !.W;
M6*Z>-#H !112:"!(*'2H8@<SWDP6SR':=79(-QEU(- W%<VS[AM;-593&;V$
M&\PI1\VVWJ?EW-)96XU47.[@F*RW2EX7L,..;*]+6]DCO5243C)3C7?':%D<
M%=N^607<R#EOU#%:)0NW^P8LIV3[R[RQ-17-$^PHLMU0XXS7AAPYC5S:T[N$
MUTA;"4VR2S/,=4]'5@=I$L_& 1]BRS'[%.0&0S<G55U$XS;RQBL5U])O_K?C
MG!M3)=-=N]YLTU0 RSP=&.)^VI_TFU%,]9]1B&3I2'TL H "(,2BEP@M:!O[
MR,86(  /-00Y5(G$!3#PB;L80 $*$\!L$(0"ZC1@ 8XA"!:P< 8V ,I9#>*8
M??)%HA1(@"%4DQ5N#!0?&4!(-N\!F$QBL*:!V(=E21/A@AS2$L 11 8)F@\2
MY:.O"GWG(0+;EUBZHY(>'I$!-3B(2[S4((+$  N.^8'NQC(0]Q@K/GE) 0N0
ML(,= .(*+P!&,(H !#UD(0L*XV,?_?A'0 92D(,D9"$->4A$)E*1BV1D(QWY
M2$A&4I*3I&0E+=G($XCL/=S1F&U^UIR&9-(A_HMQ  0E0 8+8B ^*U'8 02
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M;"*O<E2!C!& A-N!U9 @]!*9&=%4V;L/-M6P%M&!-!D$PTR^).@#AK*L!=!
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M9 LQ+: &2J>0P HC=H'TA+K'-61KOF;0*STG_CL9Y& 24*AB^;H.2)" WL,
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M&+F00@8H-- "P%%D(T-*A0<))$$4),!")F$0G7=?@AFFF&.26::99Q;%6T%
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M@H(I0"L!$*RK9B. )I$3([,#Z7%LAE8&&#1<&'&(C1K9D)_*0%DNY,TX*;N
M $!T8SN(@C^G:MK3HC:U0='51(RZK/ \( 43H)$DG20&T<'F %H9 .P ,($@
MR,!T"^E+; X 459*\@!?G<T88IF  R" -Q(0EY)VZ5:'G PI!WC86YG$_C*E
M(.179ZR51HS:&D>NCC<A;-:R1")7WLZ, !<+0 O"X%35XC>_^M4O[";2)*LM
M! )@$,U"(*I5LM8V/ Z1J%9.A\D",T:)*5R(Z68CJ $(('T%8 @%)+J0!.P&
MK,D=YD(H\YN1 KBJ5]V(N P@3Q8CY9".9!)!BD2[U-SNNQBAC)["8*W[[C?(
M0A[R*853*QW)K%9?Z((,HK4C@ZB@E@ X;LMN,V7=#L!F!A"-"%$0 :NNSK<
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M8IB%2[ (#> M"Q&6_M#[/26P'&3-+468U23@[6-!_)?HQ%5P?%%-DI<@,9U
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MFER5BUDF$XK'>^X;?+40ZMC,P 5!9N*A"/7>$<Y.[;#,/XYN>4WO..E,83(
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H&S9U9( &;  '=( '3/5T@$ (A( (B, (6,!CMP0)E( )2#7R! 0 .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
